Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Should You Be Tempted To ‘Sell’ Alexion Pharmaceuticals (ALXN) Stock

Miller Value Partners recently released its Q1 2020 Investor Letter, a copy of which you can download here. The Miller Value Partners Opportunity Equity Fund posted a return of -38.4% for the quarter (net of fees), underperforming its benchmark, the S&P 500 Index which returned -19.6% in the same quarter. You should check out Miller Value Partners top 5 stock picks for investors to buy right now, which could be the biggest winners of the stock market crash.

In the said letter, Miller Value Partners highlighted a few stocks and Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) is one of them. Alexion Pharmaceuticals is a pharmaceutical company. Year-to-date, Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) stock gained 4.3% and on June 10th it had a closing price of $116.33. Here is what Miller Value Partners said:

“We chose to sell Alexion to fund these ideas. While it still looks like a great bargain at face value, we’ve owned it for three years without the investment working. When we did an exhaustive review of how to improve our process after 2011, one useful rule was to sell a name that hadn’t worked after 2-3 years. The grandfather of value investing, Ben Graham, advocated this rule as well so we incorporated it into our process.”

Countries With Highest Medical Research Spending

In Q1 2020, the number of bullish hedge fund positions on Alexion Pharmaceuticals Inc. (NASDAQ:ALXN)  stock increased by about 17% from the previous quarter (see the chart here), so a number of other hedge fund managers don’t seem to agree with ALXN’s downside potential. Our calculations showed that Alexion Pharmaceuticals Inc. (NASDAQ:ALXN)  isn’t ranked among the 30 most popular stocks among hedge funds.

The top 10 stocks among hedge funds returned 185% since the end of 2014 and outperformed the S&P 500 Index ETFs by more than 109 percentage points. We know it sounds unbelievable. You have been dismissing our articles about top hedge fund stocks mostly because you were fed biased information by other media outlets about hedge funds’ poor performance. You could have doubled the size of your nest egg by investing in the top hedge fund stocks instead of dumb S&P 500 ETFs. Below you can watch our video about the top 5 hedge fund stocks right now. All of these stocks had positive returns in 2020.

Video: Top 5 Stocks Among Hedge Funds

At Insider Monkey we leave no stone unturned when looking for the next great investment idea. For example, 2020’s unprecedented market conditions provide us with the highest number of trading opportunities in a decade. So we are checking out stocks recommended/scorned by legendary Bill Miller. We interview hedge fund managers and ask them about their best ideas. If you want to find out the best healthcare stock to buy right now, you can watch our latest hedge fund manager interview here. We read hedge fund investor letters and listen to stock pitches at hedge fund conferences. Our best call in 2020 was shorting the market when the S&P 500 was trading at 3150 after realizing the coronavirus pandemic’s significance before most investors. You can subscribe to our free enewsletter below to receive our stories in your inbox:

Disclosure: None. This article is originally published at Insider Monkey.